Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Prothena Biosciences Limited

Prothena Therapeutics Limited

Morphosys Ag

Altrubio Inc.

Patrick Garidel

Torsten Schultz-Fademrecht

Stefan Bassarab

Andreas Langer

Karoline Bechtold-Peters

Wolfgang Friess

Richard Fuhrherr

Pamela Klein

Isaac Craig Henderson

Markus Hemminger

Ingo Michael Presser

Alexander Bauer

Nicole Denkinger

Hans-Joachim Kern

Sanjaya Singh

Barbara Enenkel

Tobias Litzenburger

Michael Grundman

Klaus-Jürgen Steffens

Steven John Padula

Bodo Brocks

Annette Bettina Galler

Andrea Eiperle

Sven Bahrenburg

Heidrun Schott

Daniel Weinfurtner

Udo Heinzelmann

Hans-Hoachim Kern

Beate Fischer

Thomas Hennes

Elaine Ee-Ling Wang

William Troy Loging

Gerald Henry Nabozny

Juergen Weber

Martin Hessling

Jürgen Weber

Sandra Zimontkowski

Torsten Schultz-fademrecht

Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

Anti-PSGL-1 antibodies and uses thereof

It is disclosed an improved multi-step process for the preparation of a highly concentrated liquid formulation containing biomolecules comprising the steps of (a) a first ultrafiltration UF1; (b) a first diafiltration DF1; (c) a second diafiltration DF2; and (d) a second ultrafiltration UF2; wherein an aqueous solution of one or more salts, as liquid medium B, is used for step (b) and water or an aqueous solution of one or more salts, as liquid medium C, is used for step (c), wherein the one or more salts used for step (b) are the same or different from the one or more salts used for step (c) and wherein the liquid medium B has an ionic strength which is higher than the ionic strength of the liquid medium C. The process according to the present invention allows the preparation of well-defined highly concentrated formulations containing biomolecules, particularly proteins, intended for pharmaceutical or non-pharmaceutical use. Unwanted excipient(s) of the starting liquid biomolecule formulation, may be reduced under solution conditions, to very low levels or levels lower than the detection limit.

Process for the preparation of concentrated liquid formulations containing biomolecules

The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.

Anti-CD19 antibody formulations

The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.

Anti-IL-23 antibodies

Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

Antibody formulations and methods

The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease.

Antibody formulations and methods for treating AL amyloidosis

The invention concerns the field of biomolecule formulation screening and stability testing. It concerns a method for the evaluation of the colloidal stability of liquid biopolymer solutions. The present invention describes a method for determining the stability of a liquid pharmaceutical composition comprising: a) providing a liquid pharmaceutical composition in a container, b) shaking said container on a shaker, whereby the shaker performs an oloid movement, c) determining the stability of said liquid pharmaceutical composition.

Method for the evaluation of the colloidal stability of liquid biopolymer solutions

The invention therefore relates to protein-containing powders, wherein the proportion of phenylalanine is at least 30% (w/w), or at least 40% (w/w). It has been shown that phenylalanine-containing powders, particularly after spray drying, are very suitable in terms of their aerodynamic characteristics and protein stabilization for preparing powders or protein compositions with improved aerodynamic properties. The main component is phenylalanine and the optional further component is an excipient which has good water-solubility compared with phenylalanine, preferably a sugar or a polyol.

Inhalable powders comprising protein, phenylalanine, and other protein stabilizers

Double chamber container for holding and combining, e.g., a lyophilizate and a liquid reconstitution medium, comprising

Dual chamber container for lyophilization, process for the filling up and use thereof

A double chamber container for holding and combining a solid lyophilizate and a liquid reconstituting medium, comprising a cylindrical body with a closure at each of the two ends, an upper displaceable closure at the reconstituting medium end, and a lower closure at the lyophilizate end, a separating stopper that can be pushed in the cylindrical body and act as a seal between the upper chamber and the lower chamber, and a bypass arranged underneath the separating stopper, with a length L that is preferably greater than the height H of the separating stopper, wherein at the upper end in the wall of the cylindrical body or in the separating stopper means are provided that allow partial connection of the interior of the cylindrical body to the environment during the lyophilization.

Dual chamber container and process for its filling up

The present invention relates to an apparatus for determining the shear sensitivity of particles in solutions and methods of determining the respective shear velocities or the respective shear stress.

Apparatus for quantifying shear stress on a formulation comprising biomolecules

The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient. The other excipient is preferably an amino acid, a peptide and/or a mono-, di- and/or oligosaccharide, wherein the oligosaccharide may be a second 1,4 O-linked saccharose derivative, provided that this is different from the first.

Powder comprising new compositions of oligosaccharides and methods for their preparation

The present invention relates to a spray-dried powder and method for its manufacture. A spray dried powder containing a pharmaceutical active substance and one or more 1,4 O-linked saccharose derivatives chosen from the compounds: 1,4 O-linked D-gal-saccharose (lactosucrose), 1,4 O-linked D-glu-saccharose (glucosyl sucrose) or 1,4 O-linked glu-glu-saccharose (maltosyl sucrose). Preferred combinations are such that they contain glucosyl and maltosyl sucrose.

Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation

Growing community of inventors

Norderstedt, Germany

Patrick Garidel